These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 15832453)

  • 1. Molecular prediction of recurrence of breast cancer.
    Tang CG; Lin AY
    N Engl J Med; 2005 Apr; 352(15):1605-7; author reply 1605-7. PubMed ID: 15832453
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH; Cosler LE; Kuderer NM; Hornberger J
    Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular prediction of recurrence of breast cancer.
    Tanvetyanon T
    N Engl J Med; 2005 Apr; 352(15):1605-7; author reply 1605-7. PubMed ID: 15832454
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualized care for patients with cancer - a work in progress.
    Bast RC; Hortobagyi GN
    N Engl J Med; 2004 Dec; 351(27):2865-7. PubMed ID: 15591336
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
    Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Ferretti G; Di Cosimo S; Giannarelli D; Carlini P; Papaldo P; Alimonti A; Fabi A; Mandalà M; Milella M; Ruggeri EM; Cognetti F
    J Clin Oncol; 2004 Feb; 22(3):568-9. PubMed ID: 14752083
    [No Abstract]   [Full Text] [Related]  

  • 9. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
    Zhang Y; Sieuwerts AM; McGreevy M; Casey G; Cufer T; Paradiso A; Harbeck N; Span PN; Hicks DG; Crowe J; Tubbs RR; Budd GT; Lyons J; Sweep FC; Schmitt M; Schittulli F; Golouh R; Talantov D; Wang Y; Foekens JA
    Breast Cancer Res Treat; 2009 Jul; 116(2):303-9. PubMed ID: 18821012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic testing for sensitivity of breast cancer to hormonal therapy.
    Symmans WF
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1954-5. PubMed ID: 16609001
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling.
    Mamounas E; Budd GT; Miller K
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):s1-s8. PubMed ID: 18516819
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
    Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
    Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
    Sieuwerts AM; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2005 Oct; 11(20):7311-21. PubMed ID: 16243802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.
    Lash TL; Gurwitz JH; Silliman RA
    J Am Geriatr Soc; 2005 Nov; 53(11):1889-96. PubMed ID: 16274369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
    Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy.
    Paik S
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1019s-1023s. PubMed ID: 16467119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.